BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 123 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2015. The put-call ratio across all filers is 0.85 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $16,560,000 | -4.9% | 3,372,674 | +1.4% | 2.76% | -8.9% |
| Q3 2017 | $17,421,000 | -6.0% | 3,324,705 | -0.3% | 3.03% | -22.4% |
| Q2 2017 | $18,537,000 | -36.2% | 3,333,958 | -3.6% | 3.91% | -48.9% |
| Q1 2017 | $29,048,000 | +12.5% | 3,458,120 | -15.2% | 7.65% | -21.3% |
| Q4 2016 | $25,819,000 | +39.2% | 4,078,895 | -3.0% | 9.72% | +73.4% |
| Q3 2016 | $18,542,000 | +191.9% | 4,204,579 | +88.0% | 5.60% | +158.1% |
| Q2 2016 | $6,353,000 | +13.7% | 2,237,066 | +13.3% | 2.17% | +7.1% |
| Q1 2016 | $5,586,000 | -73.1% | 1,973,932 | -1.8% | 2.03% | -70.4% |
| Q4 2015 | $20,748,000 | -19.7% | 2,010,501 | -9.9% | 6.85% | -14.6% |
| Q3 2015 | $25,833,000 | -23.5% | 2,230,206 | -1.4% | 8.03% | -18.3% |
| Q2 2015 | $33,762,000 | +65.3% | 2,261,361 | 0.0% | 9.83% | +6.6% |
| Q1 2015 | $20,420,000 | -25.7% | 2,261,361 | 0.0% | 9.22% | -9.4% |
| Q4 2014 | $27,498,000 | – | 2,261,361 | – | 10.17% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management, LLC | 1,744,356 | $18,455,000 | 9.59% |
| RA Capital Management | 4,347,456 | $45,996,000 | 3.30% |
| Cormorant Asset Management, LP | 1,168,000 | $12,357,000 | 2.84% |
| Baker Brothers Advisors | 5,867,031 | $62,073,000 | 0.79% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 907,920 | $9,606,000 | 0.39% |
| QVT Financial LP | 525,734 | $5,562,000 | 0.32% |
| EAM Investors, LLC | 114,548 | $1,212,000 | 0.22% |
| FRANKLIN STREET ADVISORS INC /NC | 93,000 | $984,000 | 0.20% |
| THB ASSET MANAGEMENT | 301,529 | $3,190,000 | 0.19% |
| TPG Group Holdings (SBS) Advisors, Inc. | 1,162,269 | $12,297,000 | 0.13% |